Alnylam once accused Pfizer and Moderna of infringing patents on its lipid nanoparticle technology.
In two lawsuits filed Friday, Alnylam alleged that Pfizer and Moderna profited from the generation of lipid particles he invented more than a decade ago. mobile, they unpack essential commands for the construction of mRNA proteins to create, for example, spike proteins to prepare the immune formula against Covid-19.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
We live in a new era of healthcare that advances and impacts patient outcomes and experiences. We have noticed a remarkable speed of transformative innovation, implemented studies, and complex clinical progression over the past decade.
Despite this great progress, there is still much work to be done and patients are counting on us, now more than ever, to continue this momentum. challenging diseases, adding those that today have few or no effective remedies.
CHICAGO. Novartis’ CDK4/6 inhibitor, Kisqali, helped patients with early breast cancer remain cancer-free longer after surgery, according to interim effects presented in ASCO.
In a phase III study, Kisqali was added to the endocrine cure, the existing folk remedy for patients with early breast cancer. Kisqali reduced the threat of disease relapse by 25% compared to hormonal cure alone in patients with level II or III breast cancer.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Less than two years after Takeda signed a collaboration with Poseida Therapeutics to expand six in vivo genetic treatments targeting liver and hematopoietic stem cells, Takeda will end the partnership on July 30, the company told Endpoints News.
The break is unexpected, following Takeda’s announcement in April of its goal to prevent preclinical discoveries and paintings in AAV gene therapy, as well as preclinical studies and paintings on rare hematology. these paintings.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
In an email to Endpoints News, a Catalent spokesperson showed that the company is making “a number of changes to the workforce corps” at a production facility in Bloomington, IN. While no express figure has been given to Endpoints, several local media outlets, adding that Indiana Public Media and the Bloomington Herald-Times, put the number of layoffs at 150. No publication was published in the Indiana Department of Workforce Development’s WARN notice.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Eikon Therapeutics on Thursday announced three advertising growth deals, launching a pipeline of cancer drugs for more than $100 million in new funding.
The Hayward, California-based company has one of the richest biotech startups since its founding in 2019, having raised nearly $775 million. Cells and proteins practice in action. After its Series B last year, PitchBook reported a valuation of $3. 02 billion. “a significant advance over our valuation of Series B. “
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Members of the European Parliament have called on EU countries to expand national action plans against antimicrobial resistance (AMR), calling it one of the 3 most sensitive fitness threats.
Parliament on Thursday announced recommendations to tackle AMR, adding national action plans to be updated at least every two years, an EU-wide database on AMR and antimicrobial use and greater partnership between the pharmaceutical industry, patient teams and academia.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Two biotech companies controlled a small merger on Thursday.
Berlin-based Ariceum Therapeutics acquired Britain’s Theragnostics, the corporations said, for an initial $2. 5 million in cash. Under the settlement, Ariceum will discharge one hundred percent of Theragnostics’ shares and be guilty of up to $41. 5 million in additional milestones.
Ariceum CEO Manfred Rüdiger said the deal furthers the company’s purpose of “building and progressing” a portfolio of projects, in addition to offering FDA-approved diagnostics. Greg Mullen, former CEO of Theragnostics, is now chief operating officer of Ariceum.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Despite the downsizing, pipeline and overdue rents last year, Oncorus still struggles to stay afloat and is now on the verge of bankruptcy or dissolution, the company revealed late Thursday.
The Andover, Mass. -based biotech is laying off “nearly the entire workforce of Oncorus,” after the board laid them off. CEO Ted Ashburn, chief operating officer/chief of staff Stephen Harbin and chief marketing officer John Goldberg are among the 55 leaving.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Affini-T is for a spouse for its KRAS-targeting T-cell receptor treatments near the clinic, and is recruiting a Sanofi veteran to lead the way.
The company announced Friday the appointment of Thaminda Ramanayake as Chief Commercial Officer, who was previously Vice President and Global Head of Business Development, Oncology at Sanofi. Affini-T anticipates IND submissions through the end of this year for the KRAS G12V AFNT-111 and AFNT-211, and as Ramanayake said, “there’s no better time to think about partnerships. “
KRAS is a protein that regulates the way cells grow and divide, and mutations can cause the protein to lock into the “on” position, triggering an uncontrolled expansion of malignant cells. The first generation of KRAS inhibitors, adding Amgen’s Lumakras (sotorasib) and Mirati’s Krazati (adagrasib), target a mutation called G12C to block the protein in “off” mode.
“We have an opportunity here to expand beyond the G12C,” Affini-T CEO Jak Knowles said Thursday. Affini-T was included in the Endpoints 11 list of the most productive personal biotechnology last year.
Ramanayake helped shape Sanofi’s oncology business strategy and, prior to that, was senior director of BD and strategy at BioMarin and director of global transactions at Amgen. He called his adventure a “winding road,” adding that at one point he had thought of it as a career in research, but not doing it because it was “too far from the patient. “BD, he added, is the right position “if you’re passionate about innovation, if you’re passionate about patient care. “
“The old approach of drug discovery and progression will succeed in oncology,” Ramanayake said. “You have to partner, you have to work together. “
—Nicole de Feudis
Unlock this item and others by subscribing to one of our paid plans.
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.